Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation.
High levels of VEGF and leptin are strongly linked to worse prognosis of breast cancer. Leptin signalling upregulates VEGF in human and mouse mammary tumor cells (MT), but the specific molecular mechanisms are largely unknown. Pharmacologic and genetic approaches were used to dissect the mechanism of leptin regulation of VEGF protein and mRNA in MT (4T1, EMT6 and MMT). A series of VEGF-promoter Luc-reporters (full-length and transcription factor-binding deletions) were transfected into MT to analyze leptin regulation of VEGF transcription. Deletion analysis of VEGF promoter and RNA knockdown shows that HIF-1alpha and NFkappaB are essentials for leptin regulation of VEGF. Leptin activation of HIF-1alpha was mainly linked to canonic (MAPK, PI-3K) and non-canonic (PKC, JNK and p38 MAP) signalling pathways. Leptin non-canonic signalling pathways (JNK, p38 MAP and to less extent PKC) were linked to NFkappaB activation. SP1 was involved in leptin regulation of VEGF in 4T1 cells. AP1 was not involved and AP2 repressed leptin-induced increase of VEGF. Overall, these data suggest that leptin signalling regulates VEGF mainly through HIF-1alpha and NFkappaB. These results delineate a comprehensive mechanism for leptin regulation of VEGF in MT. Disruption of leptin signalling could be used as a novel way to treat breast cancer.
Gonzalez-Perez
Ruben R
RR
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA. rgonzalez@msm.edu
Xu
Yanbo
Y
Guo
Shanchun
S
Watters
Amber
A
Zhou
Weiqiang
W
Leibovich
Samuel J
SJ
D000818:Animals; D045744:Cell Line, Tumor; D016207:Cytokines / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D020738:Leptin / Q000494:pharmacology*; D008325:Mammary Neoplasms, Experimental / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D015398:Signal Transduction; D015533:Transcriptional Activation; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000235:genetics*
D016207:Cytokines; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D020738:Leptin; D016328:NF-kappa B; D042461:Vascular Endothelial Growth Factor A
Cancer Metastasis Rev. 2000;19(1-2):139-45
11191053
Trends Cardiovasc Med. 1998 Aug;8(6):246-50
14987559
Breast Cancer Res. 2009;11(3):R36
19531256
Endocrinology. 2004 Aug;145(8):3850-7
15142989
J Biol Chem. 2008 Oct 17;283(42):28066-73
18718905
Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
15961063
Clin Cancer Res. 2004 Jul 1;10(13):4325-31
15240518
J Biol Chem. 1997 Mar 7;272(10):6093-6
9102398
FEBS Lett. 2004 May 7;565(1-3):139-42
15135067
Endocrine. 2001 Oct;16(1):21-8
11822823
J Pathol. 1999 Dec;189(4):514-20
10629551
J Biol Chem. 2004 May 7;279(19):19908-15
14985328
Immunity. 2006 Nov;25(5):701-15
17098202
Cancer Res. 2001 Jul 15;61(14):5407-14
11454684
Biochim Biophys Acta. 2002 Oct 21;1592(2):107-16
12379472
EMBO J. 1997 Feb 17;16(4):750-9
9049304
Growth Factors. 2001;19(1):19-34
11678207
Curr Med Chem. 2005;12(25):2979-94
16378500
Breast Cancer Res Treat. 2006 Jul;98(2):121-32
16752079
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92
9653127
Oncogene. 2005 Aug 25;24(36):5552-60
16007214
J Biol Chem. 1996 Feb 16;271(7):3877-83
8632007
Pharmacol Rev. 2007 Jun;59(2):185-205
17540906
J Endocrinol. 2008 Nov;199(2):221-33
18715880
Nature. 2002 Jan 17;415(6869):339-43
11797013
Acta Haematol. 2001;106(4):148-56
11815711
J Cell Physiol. 2001 Sep;188(3):304-12
11473356
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10972-7
10995484
Blood. 1999 Sep 1;94(5):1561-7
10477681
Int J Cancer. 2004 Nov 20;112(4):585-95
15382039
J Cell Physiol. 2001 Aug;188(2):223-35
11424089
Cancer Res. 1978 Oct;38(10):3174-81
210930
Mol Biol Cell. 2007 Jan;18(1):14-23
17065555
Biochem J. 2008 Jun 15;412(3):477-84
18393939
Oncogene. 2008 Jan 17;27(4):540-7
17653093
Science. 1998 Sep 11;281(5383):1683-6
9733517
Endocrinology. 2005 Nov;146(11):4917-25
16123159
Cancer Res. 1995 Nov 1;55(21):4844-9
7585518
J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11
12441326
J Biol Chem. 2003 Mar 7;278(10):8190-8
12509426
Cancer Res. 2004 Jan 15;64(2):631-8
14744778
Cancer Res. 1996 May 1;56(9):2013-6
8616842
Front Biosci. 2007 Jan 01;12:2279-90
17127464
J Biol Chem. 2002 Nov 8;277(45):42953-7
12215445
J Cell Physiol. 2003 Jan;194(1):30-44
12447987
Cell Signal. 2002 Aug;14(8):655-63
12020765
Cancer Res. 2001 Sep 15;61(18):6952-7
11559575
Cancer Res. 2002 Sep 1;62(17):4977-84
12208749
Hepatology. 2005 Dec;42(6):1339-48
16317688
Cancer Res. 2008 Dec 1;68(23):9712-22
19047149
Cancer Res. 2000 Jun 1;60(11):2898-905
10850435
Int J Cancer. 2006 Mar 15;118(6):1414-9
16206269
Clin Cancer Res. 2002 Nov;8(11):3487-95
12429639
Nature. 2004 Sep 23;431(7007):461-6
15329734
Nature. 1998 Jul 30;394(6692):485-90
9697772
Int J Cancer. 2008 Dec 15;123(12):2782-90
18798554
J Biol Chem. 1996 Nov 8;271(45):28220-8
8910439
Endocrinology. 2005 Feb;146(2):694-701
15539553
Oncogene. 2004 Feb 5;23(5):1052-63
14647449
J Biol Chem. 2006 Sep 8;281(36):26320-8
16825198
Mol Hum Reprod. 2003 Mar;9(3):151-8
12606591
Exp Biol Med (Maywood). 2003 Jun;228(6):697-705
12773701